HUTCHMED (China) Ltd
HUTCHMED (China) Ltd (HMDCF): 18 pipeline candidates · 22 clinical trials. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
18 candidates
N/A
N/A
A transparent, data-derived signal for HUTCHMED (China) Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.9B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| 100 µci [14c] hmpl-306 | Phase 1 |
| hmpl-306 | Phase 3 |
| hmpl-306 regimen | Phase 3 |
| hmpl-453 | Phase 3 |
| hmpl-506 | Phase 3 |
| hmpl-523 | Phase 3 |
| hmpl-523 | Phase 3 |
| hmpl-689 | Phase 3 |
| hmpl-760 | Phase 3 |
| hmpl-a251 | Phase 3 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in HUTCHMED (China) Ltd's pipeline?
HUTCHMED (China) Ltd (HMDCF) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HUTCHMED (China) Ltd's lead drug candidate?
HUTCHMED (China) Ltd's most advanced tracked candidate is 100 µci [14c] hmpl-306 (Phase 1) for Mass Balance Study.
What is HUTCHMED (China) Ltd's market capitalization?
HUTCHMED (China) Ltd's market capitalization is approximately $1.9B.
Who is the CEO of HUTCHMED (China) Ltd?
Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Ltd (HMDCF).
Get the full picture on HUTCHMED (China) Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.